Intelligent Ultrasound : 2022 Results Presentation

Making clinical

ultrasound EASIER to learn and SIMPLER to use

2022 Annual Results

Year ended 31 December 2022 (audited)

The distribution of this Presentation in jurisdictions other than the UK may be restricted by law and persons into whose possession this document comes should inform themselves about and observe any relevant restrictions. In particular, this document may not be published or distributed, directly or indirectly, in or into the United States of America, Canada, Australia or Japan.

This Presentation made by Intelligent Ultrasound Group Plc does not constitute an offer of, or an invitation by or on behalf of the Company or anyone else to purchase or subscribe for, any securities of or investment in the Company in any circumstances. You are reminded that any purchase of securities or investment may be made solely on the basis of your own due diligence, investigations and assessment and solely on the basis of the relevant publicly available information

and no reliance may be placed on the information contained in this document. This Presentation and the information contained within it are strictly confidential to the recipient, may not be distributed to any other person, and may not be further disclosed, copied or reproduced in any form, in whole or in part. Failure to comply with these restrictions may constitute a violation of applicable securities laws.

The information contained in this Presentation is for background purposes only, has not been independently verified by the Company nor any of the Company's directors, officers, shareholders, advisors or representatives. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. Save in the case of fraud, neither the Company nor any of its directors, officers, shareholders, advisors or representatives shall have any liability whatsoever for any loss arising from any use of this Presentation or its contents or otherwise arising in connection with this Presentation. By accepting this Presentation you agree, upon request, to return promptly all material received from the Company without retaining any copies.

This Presentation is not an invitation nor is it intended to be an inducement to engage in investment activity for the purpose of Section 21 of the Financial Services and Markets Act 2000. This Presentation does not constitute or form part of and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company in any jurisdiction or an inducement to enter into investment activity in any jurisdiction. In addition, this Presentation does not constitute a recommendation by the Company or any other person regarding any securities of, or an investment in, the Company. Neither this document nor any part thereof, nor the fact of its distribution, shall form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever.

This Presentation does not take into account the investment objectives, financial situation or particular needs of any particular investor, and it does not purport to be comprehensive or to contain all of the information that a prospective investor may desire or require in investigating the Company or an investment in the Company. Accordingly, each prospective investor should conduct its own due diligence in connection with any potential investment in the Company and seek the advice of its own professional advisors. Prospective investors must not treat the contents of this Presentation as advice relating to legal, taxation or investment matters and must make their own assessments concerning these and other consequences of any investment in the Company, including the merits of investment and the risks.

This Presentation is directed only at persons who (i) are "qualified investors" within the meaning of Article 21(1)(e) of Regulation 2017/1129/EU and any relevant implementing measures and (ii) are outside the United Kingdom, and/or (iii) have professional experience in matters relating to investments who fall within the definition of "investment professionals" contained in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order"), or are persons falling within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the Order, or fall within another exemption to the Order (all such persons referred to in (i) to (iii) above together being referred to as "Relevant Persons"). Any person who is not a Relevant Person must not act or rely on this Presentation or any of its contents. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

This Presentation may include statements that are, or may be deemed to be, "forward-looking statements". Any forward-looking statements in this Presentation reflect the Company's current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. Forward-looking statements contained in this Presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. You should not place undue reliance on forward-looking statements, which speak only as of the date of this Presentation.

2

PURPOSE

to make ultrasound, the world's fastest, safest and cheapest imaging modality, easier to learn and simpler to use

VISION

enable ultrasound for everyone

STRATEGY

continue to build our range of ultra-realistic simulators to lead the world in hi-fidelity ultrasound training

follow clinicians into the scanning room to give them AI-driven tools that enable them to scan patients faster and better

be at the forefront of using AI to enable ultrasound scanning in primary care and ultimately at-home to enable ultrasound for all

3

Overview

All financial expectations and operational milestones achieved in 2022 and a positive start in Q1 2023

AI in ultrasound is expected to be a $1.3bn market by 2028

Intelligent Ultrasound is already a first mover in this space

• SonoLyst launched on GE HealthCare's Voluson Expert 22 in Q3 22
• ScanNav Anatomy PNB received FDA clearance for sale in USA in Q4 22
• NeedleTrainer with GE's Vscan Air and PNB 2.0 launched in Q3 22

Combined with a leading ultrasound simulation business

Vision of reaching £25m by 2025, based on our unique 'Classroom to Clinic' approach

Our 2025 vision revenue is aspirational and for illustrative purposes only. It should not be construed as formal guidance.

2022 financial headlines:

Revenue	£10.1m	+ 33%
AI Revenue	£0.7m	+ 224%
Loss after tax	(£3.0)m	- 17%
Cash (as at Dec 22)	£7.2m	+ 47%

4

Making clinical

ultrasound EASIER

to learn and

SIMPLER to use

Imaging background

Since the discovery of X-Ray, medical technology has been advancing to provide images that help clinicians see inside the human body…

Of all available imaging modalities, X-Ray,MRI, CT etc., ultrasound is the fastest, cheapest, safest and its diagnostic applicability in many areas is well recognized, but…

Unlike the X-Ray,MRI, CT, ultrasound is a dynamic, real-time modality where the skills of the operator are paramount

Our vision is to make ultrasound easier to learn and simpler to use by minimising this obstacle

5